歌礼制药小分子药物ASC30临床研究获积极成果
财中社1月21日电歌礼制药（01672）发布公告，宣布其小分子口服GLP-1R激动剂ASC30在美国进行的Ia期单剂量递增研究取得积极成果。该研究在肥胖症患者中进行，显示ASC30口服片具有与剂量成比例的药代动力学特征，半衰期长达60小时，支持每日一次或更低频率的口服给药。整体安全性和耐受性良好，所有不良事件均为轻度或中度，且无3级或以上的不良事件发生。
ASC30在动物模型中的相对口服生物利用度达99%，并且在不同剂量下的药物暴露量优于其他在研小分子GLP-1R激动剂。ASC30口服片的顶线结果预计将于2025年3月底公布，进一步的Ib期多剂量递增研究也在进行中，涉及多个剂量组，预计将于2025年2月底和3月底完成。该药物的研发有望为肥胖症患者提供新的治疗选择。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10